{"filing":{"accession_number":"0001213900-26-097850","cik":"0001944552","ticker":"ANL","company_name":"Adlai Nortye Group Ltd.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"ea0304801-6k_adlai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1944552/000121390026097850/ea0304801-6k_adlai.htm"},"events":[{"id":31812,"run_id":29211,"accession_number":"0001213900-26-097850","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces two significant clinical development milestones for a clinical-stage biotech company: first patient dosed in Australia for AN4035 (initiating a global Phase I trial) and FDA IND clearance with \"Study-May-Proceed\" letter. These are material operational/regulatory achievements that advance the company's lead therapeutic candidate, but they do not fit the specific event-type categories (not earnings, M\u0026A, exec changes, impairment, litigation, or other named types). The disclosure is clearly operational—a product development and regulatory milestone—making `operational_other` the appropriate classification.","company_name":"Adlai Nortye Group Ltd.","ticker":"ANL","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34809,"accession_number":"0001213900-26-097850","item_number":"EX-99.1","item_title":"ea030480101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces two significant clinical development milestones for a clinical-stage biotech company: first patient dosed in Australia for AN4035 (initiating a global Phase I trial) and FDA IND clearance with \"Study-May-Proceed\" letter. These are material operational/regulatory achievements that advance the company's lead therapeutic candidate, but they do not fit the specific event-type categories (not earnings, M\u0026A, exec changes, impairment, litigation, or other named types). The disclosure is clearly operational—a product development and regulatory milestone—making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:02:11.809577+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34809,"accession_number":"0001213900-26-097850","item_number":"EX-99.1","item_title":"ea030480101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces two significant clinical development milestones for a clinical-stage biotech company: first patient dosed in Australia for AN4035 (initiating a global Phase I trial) and FDA IND clearance with \"Study-May-Proceed\" letter. These are material operational/regulatory achievements that advance the company's lead therapeutic candidate, but they do not fit the specific event-type categories (not earnings, M\u0026A, exec changes, impairment, litigation, or other named types). The disclosure is clearly operational—a product development and regulatory milestone—making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:02:11.809577+00:00","company_name":"Adlai Nortye Group Ltd.","ticker":"ANL","filing_date":"2026-09-08"}]}